^
Phase 2
Regeneron Pharmaceuticals
Recruiting
Last update posted :
08/03/2022
Initiation :
12/15/2021
Primary completion :
09/01/2023
Completion :
01/01/2024
HER-2 • PGR
|
HER-2 negative • PGR negative
|
Libtayo (cemiplimab) • vidutolimod (CMP-001) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
Fondazione Melanoma Onlus
Recruiting
Last update posted :
07/28/2022
Initiation :
02/10/2021
Primary completion :
10/01/2022
Completion :
02/01/2026
PD-L1
|
Libtayo (cemiplimab) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
National Cancer Institute (NCI)
Recruiting
Last update posted :
07/21/2022
Initiation :
09/18/2017
Primary completion :
06/01/2023
Completion :
06/01/2023
PD-L1 • ALK
|
ALK positive • ALK negative
|
Opdivo (nivolumab) • Imlygic (talimogene laherparepvec) • CMAB 819 (nivolumab biosimilar) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 3
Merck Sharp & Dohme LLC
Recruiting
Last update posted :
07/21/2022
Initiation :
04/01/2019
Primary completion :
05/05/2025
Completion :
09/29/2028
PD-L1
|
Keytruda (pembrolizumab) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 1
Bicara Therapeutics
Recruiting
Last update posted :
07/20/2022
Initiation :
06/01/2020
Primary completion :
12/31/2022
Completion :
06/01/2023
PD-L1
|
KRAS mutation • EGFR mutation • KRAS G12D • EGFR amplification • PD-L1 negative • RAS wild-type • KRAS G13 • KRAS G12 • EGFR negative
|
Keytruda (pembrolizumab) • BCA101 • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 1/2
Roswell Park Cancer Institute
Recruiting
Last update posted :
07/07/2022
Initiation :
12/22/2016
Primary completion :
12/09/2022
Completion :
12/09/2023
PD-L1 • ALK
|
PD-L1 expression
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • CimaVax EGF (EGF-PTI) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
Merck Sharp & Dohme LLC
Active, not recruiting
Last update posted :
07/01/2022
Initiation :
10/26/2017
Primary completion :
07/29/2020
Completion :
06/15/2023
PD-L1
|
Keytruda (pembrolizumab) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 1
Memgen, Inc.
Recruiting
Last update posted :
06/30/2022
Initiation :
02/23/2022
Primary completion :
11/01/2023
Completion :
11/01/2025
EGFR • BRAF • KRAS • ALK • ROS1
|
PD-L1 expression • BRAF V600E • EGFR mutation • BRAF V600 • ALK rearrangement
|
Invega Sustenna (paliperidone palmitate extended-release 1-month injection) • MEM-288
Phase 1
National Cancer Institute (NCI)
Suspended
Last update posted :
06/30/2022
Initiation :
02/01/2019
Primary completion :
05/30/2023
Completion :
05/30/2023
BRAF • MSI
|
BRAF mutation
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • prednisone • CS1002 (ipilimumab biosimilar) • CMAB 819 (nivolumab biosimilar) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection) • prednisone delayed-release tablet • tacrolimus intravenous • tacrolimus oral • tacrolimus topical
Phase 1
National Cancer Institute (NCI)
Recruiting
Last update posted :
06/30/2022
Initiation :
02/12/2021
Primary completion :
04/01/2026
Completion :
04/01/2026
CD4
|
PD-L1 expression
|
Keytruda (pembrolizumab) • cisplatin • elimusertib (BAY 1895344) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
University of California, San Diego
Active, not recruiting
Last update posted :
06/24/2022
Initiation :
03/28/2017
Primary completion :
11/19/2021
Completion :
05/01/2023
EGFR
|
PD-L1 expression
|
Keytruda (pembrolizumab) • Erbitux (cetuximab) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 1
Seagen Inc.
Recruiting
Last update posted :
06/10/2022
Initiation :
06/08/2020
Primary completion :
07/31/2024
Completion :
10/31/2024
HER-2
|
HER-2 negative
|
Invega Sustenna (paliperidone palmitate extended-release 1-month injection) • SGN-B6A
Phase 1/2
Falo, Louis, MD
Not yet recruiting
Last update posted :
06/10/2022
Initiation :
07/15/2022
Primary completion :
12/31/2023
Completion :
12/31/2024
IFNG • IL6 • TNFA • IL2RA • FGF • CCL4 • IL10 • IL17A • IFNA1 • IL1B
|
doxorubicin hydrochloride • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 1b
Rahul Aggarwal
Active, not recruiting
Last update posted :
05/30/2022
Initiation :
08/20/2018
Primary completion :
11/30/2023
Completion :
11/30/2023
MSI
|
MSI-H/dMMR
|
Keytruda (pembrolizumab) • abexinostat (CG-781) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 1/2
Codiak BioSciences
Recruiting
Last update posted :
05/20/2022
Initiation :
09/15/2020
Primary completion :
12/01/2022
Completion :
12/01/2022
PD-L1
|
Invega Sustenna (paliperidone palmitate extended-release 1-month injection) • exoSTING
Phase 1
Genzada Pharmaceuticals USA, Inc.
Recruiting
Last update posted :
05/18/2022
Initiation :
03/01/2019
Primary completion :
05/01/2023
Completion :
12/01/2023
HER-2 • ER • PGR
|
HER-2 negative
|
capecitabine • GZ17-6.02 • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 1
Rutgers, The State University of New Jersey
Active, not recruiting
Last update posted :
05/13/2022
Initiation :
01/31/2020
Primary completion :
09/30/2024
Completion :
09/30/2024
TMB
|
Vectibix (panitumumab) • Imlygic (talimogene laherparepvec) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase N/A
University Hospital, Bordeaux
Recruiting
Last update posted :
05/13/2022
Initiation :
02/28/2020
Primary completion :
09/28/2022
Completion :
09/28/2022
CASP3 • FLG
|
Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 1
Mayo Clinic
Recruiting
Last update posted :
04/11/2022
Initiation :
03/31/2022
Primary completion :
02/24/2024
Completion :
02/24/2025
BRAF • KRAS • ALK • TMB • MSI • ROS1 • NTRK
|
TMB-H
|
Keytruda (pembrolizumab) • cyclophosphamide • Invega Sustenna (paliperidone palmitate extended-release 1-month injection) • Leukine (sargramostim) • neoantigen peptide vaccine
Phase 2
Massachusetts General Hospital
Not yet recruiting
Last update posted :
04/07/2022
Initiation :
01/01/2023
Primary completion :
01/01/2026
Completion :
01/01/2027
CD8 • CD4 • TSLP
|
5-fluorouracil • fluorouracil topical • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
Massachusetts General Hospital
Not yet recruiting
Last update posted :
04/07/2022
Initiation :
01/01/2023
Primary completion :
01/01/2026
Completion :
01/01/2027
CD8 • CD4 • TSLP
|
5-fluorouracil • fluorouracil topical • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 1b/2
Nektar Therapeutics
Recruiting
Last update posted :
04/04/2022
Initiation :
10/30/2020
Primary completion :
06/01/2023
Completion :
08/01/2024
PD-L1 • CD8 • CD4
|
MSI-H/dMMR
|
Erbitux (cetuximab) • NKTR-255 • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
Oslo University Hospital
Recruiting
Last update posted :
04/01/2022
Initiation :
03/01/2022
Primary completion :
03/01/2034
Completion :
12/01/2034
PD-L1
|
Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
Alliance for Clinical Trials in Oncology
Recruiting
Last update posted :
03/24/2022
Initiation :
05/17/2019
Primary completion :
12/01/2022
Completion :
12/01/2023
PD-L1 • CD4
|
Erbitux (cetuximab) • Bavencio (avelumab) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
M.D. Anderson Cancer Center
Active, not recruiting
Last update posted :
03/18/2022
Initiation :
04/07/2017
Primary completion :
07/30/2022
Completion :
07/30/2022
PD-L1
|
PD-L1 expression
|
Tecentriq (atezolizumab) • Cotellic (cobimetinib) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 1/2
Turnstone Biologics, Corp.
Recruiting
Last update posted :
03/09/2022
Initiation :
06/02/2020
Primary completion :
12/30/2024
Completion :
07/30/2025
BRAF
|
PD-L1 expression
|
Keytruda (pembrolizumab) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection) • TBio-6517
Phase 1
Checkpoint Therapeutics, Inc.
Recruiting
Last update posted :
03/04/2022
Initiation :
09/20/2017
Primary completion :
11/18/2021
Completion :
12/01/2023
MSI
|
MSI-H/dMMR
|
Invega Sustenna (paliperidone palmitate extended-release 1-month injection) • cosibelimab (CK-301)
Phase 1
Shattuck Labs, Inc.
Recruiting
Last update posted :
02/07/2022
Initiation :
03/26/2019
Primary completion :
09/30/2022
Completion :
12/31/2022
EGFR • ALK • MSI
|
EGFR mutation • MSI-H/dMMR • ALK fusion
|
Invega Sustenna (paliperidone palmitate extended-release 1-month injection) • SL-279252
Phase 2
Arnaud Bewley
Recruiting
Last update posted :
01/20/2022
Initiation :
12/07/2021
Primary completion :
05/15/2024
Completion :
12/15/2026
CD4
|
Tecentriq (atezolizumab) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
Regeneron Pharmaceuticals
Active, not recruiting
Last update posted :
01/13/2022
Initiation :
04/07/2016
Primary completion :
10/19/2023
Completion :
10/19/2023
PD-L1
|
Libtayo (cemiplimab) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 1b/2a
NeoImmuneTech
Recruiting
Last update posted :
10/25/2021
Initiation :
12/26/2019
Primary completion :
02/01/2024
Completion :
05/01/2024
BRAF
|
Tecentriq (atezolizumab) • Hyleukin-7 (efineptakin alfa) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
University of Southern California
Recruiting
Last update posted :
10/18/2021
Initiation :
06/17/2020
Primary completion :
06/17/2022
Completion :
01/17/2023
PD-L1
|
Libtayo (cemiplimab) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 1b
Replimune Inc.
Recruiting
Last update posted :
09/14/2021
Initiation :
05/15/2020
Primary completion :
02/01/2024
Completion :
06/01/2024
CTLA4
|
vusolimogene oderparepvec (RP1)
Phase 1
Mayo Clinic
Recruiting
Last update posted :
08/30/2021
Initiation :
02/13/2020
Primary completion :
07/31/2022
Completion :
07/31/2022
EGFR • BRAF • PD-L1 • ALK • MSI
|
PD-L1 expression • MSI-H/dMMR
|
Keytruda (pembrolizumab) • Odomzo (sonidegib) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
Stanford University
Recruiting
Last update posted :
07/02/2021
Initiation :
06/22/2021
Primary completion :
06/01/2024
Completion :
11/01/2024
PD-L1
|
Tecentriq (atezolizumab) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 1b
Turnstone Biologics, Corp.
Withdrawn
Last update posted :
04/06/2021
Initiation :
02/15/2020
Primary completion :
10/30/2020
Completion :
12/31/2021
MAGEA3
|
Keytruda (pembrolizumab) • cyclophosphamide • Marabex (MAGE-A3 vaccine) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
Salzburger Landeskliniken
Active, not recruiting
Last update posted :
03/17/2021
Initiation :
03/06/2017
Primary completion :
03/31/2021
Completion :
12/01/2023
PD-L1
|
PD-L1 expression
|
Opdivo (nivolumab) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
Assistance Publique - Hôpitaux de Paris
Completed
Last update posted :
01/13/2021
Initiation :
03/27/2017
Primary completion :
03/23/2019
Completion :
12/15/2020
PD-L1
|
PD-L1 expression
|
Keytruda (pembrolizumab) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
Case Comprehensive Cancer Center
Completed
Last update posted :
11/16/2020
Initiation :
05/10/2017
Primary completion :
06/26/2020
Completion :
09/09/2020
ALB
|
Keytruda (pembrolizumab)
Phase 1
Emory University
Recruiting
Last update posted :
06/30/2020
Initiation :
05/15/2020
Primary completion :
10/01/2030
Completion :
10/01/2030
ALB
|
Libtayo (cemiplimab)
Phase 1/2
OHSU Knight Cancer Institute
Withdrawn
Last update posted :
11/19/2014
Initiation :
12/01/2011
Primary completion :
09/01/2013
Completion :
09/01/2013
EGFR
|
EGFR expression
|
erlotinib • linsitinib (ASP7487)